Aerska
About
Aerska is a Dublin-based RNA medicines biotech company that uses proprietary brain shuttle technology to overcome the blood-brain barrier and deliver RNAi therapies for neurological diseases such as Alzheimer's and Parkinson's. Founded in 2025 by Jack O'Meara, Dave Hardwicke, and Stu Milstein, the company emerged from stealth in October 2025 with a $21 million seed round, then closed a $39 million Series A in February 2026 led by EQT Dementia Fund and age1, bringing total funding to $60 million.
Recent news
- Irish BioTech startup Aerska raises €32 million Series A to deliver RNA meds to the brain 2026-02-01 · EU-Startups
- Irish biotech start-up Aerska raises $21m in seed funding 2025-10-01 · The Irish Times
- Irish biotech launches with $21M to shuttle RNAi meds to brain 2025-10-01 · Fierce Biotech
Know Aerska?
We list a record's team, investors, portfolio and events once we can verify them. Send us what you know and we'll check it.
Suggest an edit